Citation Impact
Citing Papers
The gut microbiota and host health: a new clinical frontier
2015 Standout
Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
2015
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
2014
The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
2018
Ontology and Function of Fibroblast-Like and Macrophage-Like Synoviocytes: How Do They Talk to Each Other and Can They Be Targeted for Rheumatoid Arthritis Therapy?
2018
Osteoporosis
2019 Standout
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2013
Targeting Interleukin-6 Signaling in Clinic
2019
Rheumatoid arthritis
2018 Standout
Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection
2016
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Rheumatoid arthritis
2016 Standout
Synovial Tissue Inflammation Mediated by Autoimmune T Cells
2019 StandoutNobel
Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens
2006 Standout
European evidence based consensus for endoscopy in inflammatory bowel disease
2013 Standout
Medicinal chemistry of adenosine, P2Y and P2X receptors
2015
TNF inhibitor therapy for rheumatoid arthritis
2012
Pro-resolving lipid mediators are leads for resolution physiology
2014 StandoutNature
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
2019 Standout
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
2015
Epigenetic regulation of Th1 and Th2 cell development
2005
Therapeutic applications of compounds in the Magnolia family
2011 Standout
Molecular mechanisms regulating NLRP3 inflammasome activation
2015 Standout
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
2020 Standout
Psoriasis
2021 Standout
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
2013
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
2013
The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease
2014
Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
2012
Therapeutic antibodies for autoimmunity and inflammation
2010
Antibody therapy of cancer
2012 Standout
Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis
2012
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
The P2X7 Receptor in Infection and Inflammation
2017
IL-6 in Inflammation, Immunity, and Disease
2014 Standout
Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis
2013 StandoutNobel
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
2014
Crohn's disease
2016 Standout
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
2017
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
2012
Ulcerative colitis
2016 Standout
The use of spirocyclic scaffolds in drug discovery
2014 Standout
Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
2015
Functional Specialization of Interleukin-17 Family Members
2011 Standout
Proposal for a new nomenclature of disease-modifying antirheumatic drugs
2013
Hidradenitis suppurativa
2020 Standout
Mechanisms and Functions of Inflammasomes
2014 Standout
Ulcerative colitis
2020 Standout
Effector function of type II collagen–stimulated T cells from rheumatoid arthritis patients: Cross‐talk between T cells and synovial fibroblasts
2004
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
2012
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
2017
The changing landscape of biosimilars in rheumatology
2016
TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future
2014
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
2013
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
2017
Serum uric acid and the risk of cardiovascular and renal disease
2015
The global burden of IBD: from 2015 to 2025
2015 Standout
Immunopathogenesis of Collagen Arthritis
2003
The biosimilar road in inflammatory bowel disease: The right way?
2014
A systematic review of intervention thresholds based on FRAX
2016
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
Honokiol, a Multifunctional Antiangiogenic and Antitumor Agent
2009 Standout
Ion Channels as Therapeutic Targets: A Drug Discovery Perspective
2012
Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
2015
Monoclonal Antibodies for Cancer Therapy
2012 StandoutNobel
Expression of IL-17 Homologs and Their Receptors in the Synovial Cells of Rheumatoid Arthritis Patients
2005
Ion Channels in Innate and Adaptive Immunity
2015
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
2019 Standout
Cytokine Storm
2020 Standout
Piezo1 channels restrain regulatory T cells but are dispensable for effector CD4 + T cell responses
2021 Standout
Honokiol, a Natural Plant Product, Inhibits Inflammatory Signals and Alleviates Inflammatory Arthritis
2007 Standout
Computational Evolution of Threonine-Rich β-Hairpin Peptides Mimicking Specificity and Affinity of Antibodies
2019 StandoutNobel
Etanercept for the Treatment of Rheumatoid Arthritis
2018
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
2020 Standout
Explainable Artificial Intelligence (XAI): What we know and what is left to attain Trustworthy Artificial Intelligence
2023 Standout
Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases
2017
Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine
2016 StandoutNobel
TNF inhibitors – Mechanisms of action, approved and off-label indications
2014
2020 International Society of Hypertension Global Hypertension Practice Guidelines
2020 Standout
Industry sponsorship and research outcome
2017 Standout
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
Works of Won Park being referenced
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
2013
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
2016
Efficacy and Safety of CE-224,535, an Antagonist of P2X7Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate
2012
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
2016
Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial
2015
Shift toward T helper 1 cytokines by type II collagen-reactive T cells in patients with rheumatoid arthritis
2001
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
2013
Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis
2009
Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study
2015
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
2016
A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study
2016
IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis.
2000
A Comparison of Three Different Guidelines for Osteoporosis Treatment in Patients with Rheumatoid Arthritis in Korea
2010
A Clinical Trial and Extension Study of Infliximab in Korean Patients with Active Rheumatoid Arthritis despite Methotrexate Treatment
2013
Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy
2014